SOLV 8-K SEC Filing Analysis

Latest settled — T+5d

SOLV ▲ +8.53% at T+5d

NEUTRAL call ✓ call won +8.53% · α vs SPY +8.22% · entry $75.94 → $82.42

Next anchor: T+20d in 12d

Currently $78.87 · +3.86% from $75.94 entry

Entry anchored
May 27, 2026
via day open

T+1d

-1.30%

call -1.30% · α -1.54%

$74.95

settled 16d ago

T+5d

+8.53%

call +8.53% · α +8.22%

$82.42

settled 10d ago

T+20d

—

call — · α —

—

in 12d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Solventum adopted a new executive severance plan effective June 1, 2026, replacing the prior plan. The plan provides severance benefits (9–24 months base salary, prorated incentive, COBRA lump sum, and equity treatment) for eligible employees upon involuntary termination or resignation for good reason. No departures or appointments were announced; this is a routine compensatory arrangement update.

Actionable Insight

The plan is a routine update with no immediate stock price catalyst. Monitor for any future executive departures that would trigger severance payouts; otherwise, no trading action required.

Key Facts

Talent Committee adopted new Solventum Executive Severance Plan on May 21, 2026, effective June 1, 2026.
Plan replaces prior executive severance plan dated April 1, 2024.
Eligible employees: U.S. common law employees at job grade L3 or above.
CEO severance: 24 months base salary plus prorated annual incentive and COBRA lump sum.
CEO direct reports (current execs eligible for 18-month severance until May 31, 2028; otherwise 12 months).
Other eligible employees: L1/L2 (not CEO direct reports) get 12 months; L3 get 9 months base salary.
Post-effective-date annual RSU awards forfeited on termination; pre-effective-date awards get accelerated vesting based on service.
COBRA premium lump sum provided for CEO and direct reports; others also receive lump sum.
Plan includes standard provisions: claims procedure, 280G/409A compliance, clawback, amendment/termination rights.

Financial Impact

No dollar amounts disclosed; severance costs depend on future terminations. Plan is consistent with prior practice and not expected to materially change aggregate compensation expense.

Risk Factors

Potential cash outflow if multiple eligible executives are terminated involuntarily.
Change-in-control provisions could increase payout exposure in a takeover scenario.

Market Snapshot

Exchange

NYSE

Sector

Surgical & Medical Instruments & Apparatus

Analyst Consensus

52% bullish (21 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001964738-26-000031
Document: solv-20260521.htm	0001964738-26-000031
Document: 0001964738-26-000031-index-headers.html	0001964738-26-000031
Document: 0001964738-26-000031-index.html	0001964738-26-000031
Document: 0001964738-26-000031.txt	0001964738-26-000031

4 reports for SOLV

T+1T+5T+20T+60

Filters

Reports for SOLV — sortable, filterable
	Type				Now
Jun 12, 2026 1d ago	Institutional Cluster MIXED ★ 5/10	$79.23 awaiting T+5	awaiting T+5	—	$78.87 (−0.45%)
Jun 5, 2026 7d ago	8-K NEUTRAL ★ 2/10	$83.01 awaiting T+5	awaiting T+5	—	$78.87 (−4.99%)
May 27, 2026 16d ago	8-K NEUTRAL ★ 3/10	$75.94 $82.42	▲ +8.53%	▲ +8.22%	$78.87 (+3.86%)
May 5, 2026 5w ago	8-K MIXED ★ 6/10	$70.99 $75.10	▲ +5.79%	▲ +4.66%	$78.87 (+11.10%)

US Market Status

Market Closed — Opens Mon (47h 58m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access